Nuevolution maintains guidance despite million-dollar loss

Sales stood still during the first half of Nuevolution’s staggered financial year. It resulted in a loss of DKK 46 million. However, the CEO assures that the company is still going strong. “That’s biotech,” he says.

Photo: Nuevolution PR

Log in to read our articles

Welcome to MedWatch. A part of our content is exclusive and reserved for our users.

Try us for 14 days

Try a trial subscription for access to our quality journalism

Related articles